|  | Tobacco/nicotine use status | χ2 | p-valuea | ||
---|---|---|---|---|---|---|
Total | Never | Former | Current | |||
N = 4040 | n = 3482 | n = 79 | n = 479 | |||
n (%) | n (%) | n (%) | n (%) | |||
Pre-existing medical condition, yes | 701 (17.4) | 623 (17.9) | 19 (24.1) | 59 (12.3) | 7.433 | 0.006 |
Contact with a confirmed case, yesb | 1558 (38.6) | 1361 (39.1) | 31 (39.2) | 166 (34.7) | 3.505 | 0.173 |
Symptoms, yesb | 1224 (30.3) | 1088 (31.2) | 27 (34.2) | 109 (22.8) | 14.949 | 0.001 |
Hospitalized, yesb | 120 (3.0) | 102 (2.9) | 2 (2.5) | 16 (3.3) | 0.301 | 0.860 |
Symptoms severityb | n = 1224 | n = 1088 | n = 27 | n = 109 |  |  |
 Mild | 652 (53.3) | 575 (52.8) | 17 (63.0) | 60 (55.0) | 1.728 | 0.786 |
 Moderate | 459 (37.5) | 411 (37.8) | 9 (33.3) | 39 (35.8) | ||
 Severe | 113 (9.2) | 102 (9.4) | 1 (3.7) | 10 (9.2) | ||
SARS-Co-V2 test result | ||||||
 Negative | 3770 (93.3) | 3239 (93.0) | 75 (94.9) | 456 (95.2) | 3.410 | 0.065 |
 Positive at baseline | 170 (4.2) | 152 (4.4) | 3 (3.8) | 15 (3.1) | ||
 Positive at follow-up | 100 (2.5) | 91 (2.6) | 1 (1.3) | 8 (1.7) | ||
Among total SARS-CoV-2 positive | n = 270 | n = 243 | n = 4 | n = 23 |  |  |
Symptoms, yesb | 109 (40.4) | 100 (41.2) | 2 (50.0) | 7 (30.4) | 1.159 | 0.560 |
Symptoms severityb | n = 109 | n = 100 | n = 2 | n = 7 |  |  |
 Mild | 40 (36.7) | 36 (36.0) | 1 (50.0) | 3 (42.9) | 1.508 | 0.911 |
 Moderate | 55 (50.5) | 50 (50.0) | 1 (50.0) | 4 (57.1) | ||
 Severe | 14 (12.8) | 14 (14.0) | 0 (0.0) | 0 (0.0) |